Trial Profile

Allergen challenge Study of AQST-109

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 04 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Sep 2024 According to an Aquestive Therapeutics media release, company outlined that it has completed enrollment in its remaining supportive study for Anaphylm, the oral allergy syndrome (OAS) challenge study, which is expected to be completed in the fourth quarter of 2024 following the completion of dosing.
14 Aug 2024 According to an Aquestive Therapeutics media release, company is currently conducting its remaining supportive study for Anaphylm, the oral allergy syndrome (OAS) challenge study, which is expected to be completed late in the third quarter or early fourth quarter of 2024.
25 Jun 2024 According to an Aquestive Therapeutics media release, initial dosing is expected to occur in July 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com